Research programme: CNS and neurological disorder therapeutics - ACADIAAlternative Names: AC-131; AC-186; ERβ programme - ACADIA; Estrogen receptor beta agonists - ACADIA; Nurr1 programme - ACADIA; Nurr1-retinoid X receptor agonists - ACADIA; Nurr1-RXR agonists - ACADIA
Latest Information Update: 24 Dec 2012
At a glance
- Originator ACADIA Pharmaceuticals
- Class Small molecules
- Mechanism of Action Dopamine modulators; Estrogen receptor beta agonists; Nuclear receptor subfamily 4 group A member 2 agonists; Retinoid X receptor agonists; Selective estrogen receptor beta agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Multiple sclerosis; Neuropathic pain; Parkinson's disease